The treatment of primary glomerular diseases is highly variable and is often complicated due to drug resistance, relapses and drug toxicity. Various immunosuppressive drugs have been tried, but there is as yet no superiority of any single drug. Mycophenolate mofetil is a relatively new drug which has shown some superiority in renal transplantation and lupus nephritis. It has an advantage of relatively less side effects with no nephrotoxicity. This article reviews the recent literature on the effect of this drug in managing primary glomerular diseases.